Advertisement
Perspective

Perspective Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online.

See all article types »

GeneXpert—A Game-Changer for Tuberculosis Control?

  • Carlton A. Evans mail

    carlton.evans@ifhad.org

    Affiliations: Universidad Peruana Cayetano Heredia, Lima, Peru, Imperial College London Hammersmith Hospital Campus, London, United Kingdom, IFHAD: Innovation For Health And Development, London, United Kingdom

    X
  • Published: July 26, 2011
  • DOI: 10.1371/journal.pmed.1001064

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study

Lesley E. Scott, Kerrigan McCarthy, Natasha Gous, Matilda Nduna, Annelies Van Rie, Ian Sanne, Willem F. Venter, Adrian Duse, Wendy Stevens
Research Article | published 26 Jul 2011 | PLOS Medicine
doi:10.1371/journal.pmed.1001061

Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis

David W. Dowdy, Adithya Cattamanchi, Karen R. Steingart, Madhukar Pai
Essay | published 26 Jul 2011 | PLOS Medicine
doi:10.1371/journal.pmed.1001063

Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study

Stephen D. Lawn, Sophie V. Brooks, Katharina Kranzer, Mark P. Nicol, Andrew Whitelaw, Monica Vogt, Linda-Gail Bekker, Robin Wood
Research Article | published 26 Jul 2011 | PLOS Medicine
doi:10.1371/journal.pmed.1001067